At the end of 3-week mavorixafor monotherapy, expression scores for a panel of antigen processing and presentation genes measured in melanoma biopsies, which included B2M, TAP1/TAP2, and multiple HLA complex genes, trended toward an increase (Fig. 4C). This evidence concerns the gene TAP2 and melanoma.